Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

DES MOINES, Iowa, Jan. 7, 2025 /PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its 2025 selections for the industry's most promising up-and-coming companies.

“The OECS remains committed to the sustainable development of the region. The health of our environment is key to this, and ...

This story incorporates reporting fromBoston.com, Philadelphia Inquirer, The Boston Globe, pharmaphorum, Hartford Courant, BioSpace and Yahoo.